Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2024 Jul 27

PMID 39064541

Authors

Bibhuti B Das

Affiliations

Soon will be listed here.

Abstract

This review article examines the mechanism of action of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) and Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2is) in managing chronic right ventricular (RV) dysfunction. Despite advancements in heart failure (HF) treatment, RV dysfunction remains a significant contributor to morbidity and mortality. This article explores the The article explores the impact of ARNIs and SGLT2is on RV function based on clinical and preclinical evidence, and the potential benefits of combined therapy. It highlights the need for further research to optimize patient outcomes and suggests that RV function should be considered in future clinical trials as part of risk stratification for HF therapies. This review underscores the importance of the early initiation of ARNIs and SGLT2is as per guideline-directed medical therapy for eligible HFrEF and HFpEF patients to improve co-existing RV dysfunction.

Citing Articles

Novel Therapies for Right Ventricular Failure.

Das B Curr Cardiol Rep. 2025; 27(1):26.

PMID: 39825962 DOI: 10.1007/s11886-024-02157-9.

References

Ephrem G, McCollum J, Green-Hess D, Guglin M, Sawada S, Rao R . Subjective and Objective Impact of Angiotensin Receptor-Neprilysin Inhibitors on Systemic Right Ventricle Patients. Heart Lung Circ. 2022; 31(7):964-973. DOI: 10.1016/j.hlc.2022.02.005. View

Dini F, Carluccio E, Simioniuc A, Biagioli P, Reboldi G, Galeotti G . Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2016; 18(12):1462-1471. DOI: 10.1002/ejhf.639. View

Bozkurt B, Coats A, Tsutsui H, Abdelhamid C, Adamopoulos S, Albert N . Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal.... Eur J Heart Fail. 2021; 23(3):352-380. DOI: 10.1002/ejhf.2115. View

Modesti P, Vanni S, Bertolozzi I, Cecioni I, Lumachi C, Perna A . Different growth factor activation in the right and left ventricles in experimental volume overload. Hypertension. 2003; 43(1):101-8. DOI: 10.1161/01.HYP.0000104720.76179.18. View

Winter M, Bouma B, Groenink M, Konings T, Tijssen J, van Veldhuisen D . Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure. Heart. 2008; 95(12):960-3. DOI: 10.1136/hrt.2008.156265. View

Wu J, Liu T, Shi S, Fan Z, Hiram R, Xiong F . Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol. 2022; 21(1):197. PMC: 9516842. DOI: 10.1186/s12933-022-01614-5. View

Llucia-Valldeperas A, van Wezenbeek J, Goumans M, de Man F . The battle of new biomarkers for right heart failure in pulmonary hypertension: is the queen of hearts NT-proBNP defeated at last?. Eur Respir J. 2021; 57(4). DOI: 10.1183/13993003.04277-2020. View

Fusco F, Scognamiglio G, Abbate M, Merola A, Grimaldi N, Ciriello G . Dapagliflozin in Patients With a Failing Systemic Right Ventricle: Results From the DAPA-SERVE Trial. JACC Heart Fail. 2024; 12(4):789-791. DOI: 10.1016/j.jchf.2024.01.006. View

Neijenhuis R, MacDonald S, Zemrak F, Mertens B, Dinsdale A, Hunter A . Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease. J Am Coll Cardiol. 2024; 83(15):1403-1414. DOI: 10.1016/j.jacc.2024.02.017. View

10.

Liao J, Ebrahimi R, Ling Z, Meyer C, Martinek M, Sommer P . Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol. 2024; 23(1):78. PMC: 10893620. DOI: 10.1186/s12933-024-02137-x. View

11.

Egorova A, Nederend M, Tops L, Vliegen H, Jongbloed M, Kies P . The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail. 2022; 9(3):2007-2012. PMC: 9065858. DOI: 10.1002/ehf2.13871. View

12.

Lin Y, Zhang H, Zhao S, Chen L, Li J, Wang X . The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and.... Front Cardiovasc Med. 2022; 9:882089. PMC: 9157547. DOI: 10.3389/fcvm.2022.882089. View

13.

Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J . Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail. 2012; 18(3):216-25. DOI: 10.1016/j.cardfail.2011.12.003. View

14.

Stout K, Broberg C, Book W, Cecchin F, Chen J, Dimopoulos K . Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation. 2016; 133(8):770-801. DOI: 10.1161/CIR.0000000000000352. View

15.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

16.

Fusco F, Scognamiglio G, Sorice D, Abbate M, Altobelli I, Sarubbi B . Biventricular performance in adults with a systemic right ventricle: new insights from myocardial work analysis. Int J Cardiovasc Imaging. 2024; 40(5):1067-1079. DOI: 10.1007/s10554-024-03076-0. View

17.

Appadurai V, Thoreau J, Malpas T, Nicolae M . Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry. Heart Lung Circ. 2019; 29(1):137-141. DOI: 10.1016/j.hlc.2018.12.003. View

18.

Murphy S, Prescott M, Camacho A, Iyer S, Maisel A, Felker G . Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2020; 9(2):127-136. DOI: 10.1016/j.jchf.2020.09.013. View

19.

Myhre P, Vaduganathan M, Claggett B, Packer M, Desai A, Rouleau J . B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019; 73(11):1264-1272. PMC: 7955687. DOI: 10.1016/j.jacc.2019.01.018. View

20.

Miranda W, Jain C, Egbe A, Reddy Y, Dearani J, Hagler D . Hemodynamics in Adults with Systemic Right Ventricles: Differences Between Congenitally Corrected and Complete Transposition of the Great Arteries. Pediatr Cardiol. 2024; 46(1):189-197. DOI: 10.1007/s00246-023-03381-w. View